Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-97

HIV Medicine

Volumn 1, Issue 1, 1999, Pages 32-39

  Mocroft, A ^a,b   Sabin, C A ^a,b   Youle, M ^a,b   Swaden, L ^a,b   Tyrer, M ^a,b   Wilson, D ^a,b   Madge, S ^a,b   Johnson, M A ^a,b   Phillips, A N ^a,b  

^a Department of Primary Care and Population Sciences ^*  (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HIV AGENTS; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; RETROSPECTIVE STUDY; STANDARD; UNITED KINGDOM;

ADULT; ANTI-HIV AGENTS; CLINICAL PROTOCOLS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMAN; LONDON; MALE; MIDDLE AGE; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 0033206977     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.1999.00006.x     Document Type: Article

References (38)

1. Fischl MA, Richman D, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317: 185-191.
2. Volberding PA, Lagakos SW, Koch MA, etal. Zidovudine in asymptomatic human immunodeficiency virus infection. N EnglJMed 1990; 322: 941-949.
3. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581-587.
4. Fischl MA, Oison RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993; 118: 762-769.
5. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993; 119: 786-793.
6. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therpay in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre. N Engl J Med 1996; 335: 1801-1090.
7. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996; 348: 283-291.
8. Saravolitz LD, Winslow DL, Collins G, etal. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1099-1106.
9. Anonymous. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection. The CAESAR Trial. Lancet 1997; 349: 1413-1421.
10. Cameron DW, Heath-Chiozzi M, Danner S, etal. Randomised placebo controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351: 543-549.
11. Hammer SM, Squires KE, etal. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med 1997; 337: 725-733.
12. Gullick RM, Mellors JM, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-739.
13. Collier AC, Coombs RVV, Schoenfield DA, etal Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996; 334: 1011-1017.
14. Gullick RM, Mellors JW, Havlir D, etal. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine forHIV-1 infection. JAMA 1998; 280: 35-41.
15. Gazzard B, Moyle G, on behalf of the BHIVA guidelines Writing Committee. 1998 revision to the British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-316.
16. Carpenter CCJ, Fischl MA, Hammer SM, etal. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA 1998; 280: 78-86.
17. Kirk 0, Mocroft A, Katzenstein T, etal. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS 1998; 12: 2031-2039.
18. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France 1995-1997. JAIDS 1998; 18: 358-364.
19. SAS Institute Inc. SAS/STAT Users Guide, version 6, 4th edn, vol 2. Cary, NC, SAS Institute Inc., 1989.
20. Fischl MA, Richman DD, Hansen N, etal. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990; 112: 727-737.
21. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343: 871-881.
22. Phillips AN, Katlama C, Barton S, etal. Survival in 2367 zidovudine treated patients according to use of other nucleoside analogue drugs. JAIDS 1998; 17: 239-244.
23. Montaner JSG, Hogg RS, Yip B, Gatari N, Schlechter MT, O'Shaughnessy MV. Increased zidovudine prescribing associated with lamivudine availability. JAMA 1996; 275: 598.
24. Carpenter CCI, Fischl MA, Hammer SN, etal. Antiretroviral therapy for HIV in 1996: recommendations of an international panel. JAMA 1996; 276: 146-154.
25. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological failure in patients
26. with HIV starting a protease inhibitor. AIDS 1998; 12: 2161-2167.
27. Kirk 0. Preliminary comparison of outcome in patients starting either ritonavir, indihavir (I) or saquinavir (S) in 1749 patients from the Eurosida study. 12th World AIDS Conference, Genera, 28 June-3 July 1998. Abstract 12273.
28. Egger M, Telenti A, Wirz M, Battegay M. Disease progression and survival on triple therapy: indinavir, ritonavir or saquinavir combined with 3TC and AZT. 12th World AIDS Conference, Genera, 28 June-3 July 1998. Abstract 12317.
29. Grabar S, Costagliola D. Factors associated with progression to a new AIDS defining event or death in patients receiving a protease inhibitor. 12th World AIDS Conference, Geneva, 28 June-3 July 1998. Abstract 12282.
30. Tomini C, Vella S, Fragola FV, eraJ. A multicenter randomised study comparing ritonavir and indinavir in 1251 previously treated patients with CD4 below 50/mm3 (Italian ISS-IP1 Study Group). 12th World AIDS Conference, Geneva, 28 June-3 July 1998. Abstract 12237.
31. Pedersen C, Gerstoft J, Lundgren JD, eraJ. Saquinavir/ritonavir may have better antiviral efficacy than either ritonavir or indinavir in HIV infected antiretroviral naïve patients. 12th World AIDS Conference, Geneva, 28 June-3 July 1998. Abstract 12221.
32. Boucher CAB, Borleffs J, on behalf of the CHEESE Study Group. Long-term evaluation of saquinavir soft-gel-capsule or indinavir as part of combination triple therapy (CHEESE study). 12th World AIDS Conference, Geneva, 28 June-3 July 1998. Abstract 12267.
33. Decks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277: 145-153.
34. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors (letter). Lancet 1998; 351: 1328.
35. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351: 867-870.
36. Anonymous. Update: rrends in AIDS incidence-United States 1996. MMWR 1997; 46: 861-867.
37. Mouton Y, Alfandari S, Valette M, étal. Impact of protease inhibitors on AIDS defining events and hospitalisations in 10 French AIDS reference centres. AIDS 1997; 11: F101-F105.
38. Swaden LS, Wake A, Johnson MA. The impact on drug budgets and patient care patterns of the introduction of triple therapy. 4th Annual Meeting of the British HIV Association (BHIVA), 27-29 March, UK. Abstract 025.